PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing
The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with metastatic breast cancer.
Upon completion of this activity, participants should be able to:
- Describe the mechanism of action of the different PARP inhibitors and the rationale for PARP inhibition in treating metastatic breast cancer
- Identify patients based on molecular changes and previous therapy that are most likely to benefit from treatments with PARP inhibitors
- Integrate single-agent PARP inhibitors into the treatment of appropriately selected patients with metastatic breast cancer
- Refer eligible patients with metastatic breast cancer to clinical trials of single-agent PARP inhibitors and combinations of PARP inhibitors with other anticancer therapies
Lee Schwartzberg, MD, FACP
West Cancer Center
Professor of Medicine
University of Tennessee Health Science Center
Jennifer K. Litton, MD
Associate Professor of Medicine
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Mark E. Robson, MD
Chief, Breast Medicine Service
Attending Physician, Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.
The faculty, NCCN staff, and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
Jennifer K. Litton, MD, has disclosed that she has received funds for research support from AstraZeneca, EMD Serono, Genentech, GlaxoSmithKline, and Pfizer and has served on advisory boards (uncompensated) for AstraZeneca and Pfizer.
Mark E. Robson, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, BioMarin, and Medivation and consulting fees from AstraZeneca and McKesson.
Lee Schwartzberg, MD, FACP, has disclosed that he has served as a scientific advisor for Bristol-Myers Squibb Company and has received consulting fees/honoraria from Genentech, Genomic Health, and Pfizer.
The activity planning staff listed below discloses no relevant financial relationships:
CCO: Timothy Quill, PhD; Gordon Kelley; Rachael M. Andrie, PhD; Kevin Obholz, PhD
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CMP, CHCP
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Rashmi Kumar, PhD; Susan D. Darlow, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 2.0 contact hours.
NCCN designates this knowledge-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. JA4008196-9999-19-004-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
- 2.00 AAPA Category 1 CME credit
- 2.00 ACPE contact hours
- 2.00 AMA PRA Category 1 Credit™
- 2.00 ANCC contact hours
- 2.00 Participation